Physician profile
Chase King
NPI 1376907386
$7,157.46
in general payments reported to CMS, 2019-2025
30 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.57 · 2020: $37.33 · 2021: $124 · 2022: $1,039 · 2023: $4,431 · 2024: $968 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,603 · Travel and Lodging: $2,007 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.21 |
| Travel and Lodging | $2,006.66 |
| Education | $304.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $3,337.62 | 2023 | Edora 8 Dr-T, Sentus, Acticor 7 Vr-T Dx |
| Abbott Laboratories | $604.82 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $553.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $525.26 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $372.66 | 2021-2025 | |
| Abbvie INC. | $364.09 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $354.72 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Medtronic, INC. | $238.42 | 2022-2024 | Azure Xt Dr Mri Surescan |
| Otsuka America Pharmaceutical, INC. | $114.81 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $93.56 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $69.81 | 2023-2024 | Veozah |
| Insulet Corporation | $60.84 | 2024-2025 | Omnipod |
| Corcept Therapeutics | $60.76 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $57.30 | 2022-2024 | Trintellix |
| Horizon Therapeutics Plc | $31.07 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.64 | 2023 | |
| Phathom Pharmaceuticals, INC. | $30.42 | 2024 | Voquezna |
| Allergan, INC. | $29.99 | 2019 | |
| Dexcom, INC. | $27.59 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $25.59 | 2022 | |
| Tactile Systems Technology INC | $24.01 | 2024 | Flexitouch Plus, Entre Plus |
| Sanofi-Aventis U.S. LLC | $20.13 | 2023 | |
| Amgen INC. | $19.69 | 2023 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $18.73 | 2025 | Auvelity |
| Lundbeck LLC | $18.73 | 2025 | Rexulti |
| Biosense Webster, INC. | $16.18 | 2025 | Carto 3 |
| Glaxosmithkline, LLC. | $15.57 | 2025 | Shingrix |
| Novartis Pharmaceuticals Corporation | $14.56 | 2022 | |
| Amarin Pharma, INC. | $13.79 | 2021 | |
| Gilead Sciences, INC. | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.